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Encoded by a single gene, PEDF is a 50kDa glycoprotein that is highly conserved and is widely expressed among many tissues.
Most secreted PEDF deposits within the extracellular matrix, with cell-type-speciﬁc functions. While traditionally PEDF is known
as a strong antiangiogenic factor, more recently, as this paper highlights, PEDF has been linked with stem cell biology, and there
is now accumulating evidence demonstrating the eﬀects of PEDF in a variety of stem cells, mainly in supporting stem cell survival
and maintaining multipotency.
1.Introduction
1.1. Introduction to PEDF. Pigment-epithelium-derived fac-
tor (PEDF) is a glycoprotein that belongs to the superfamily
of serpin protease inhibitor proteins without inhibitory
function, encoded by the gene SERPINF1 located on chro-
mosome 17p13 which is well conserved in evolution [1].
It is a protein of 418 amino acids, with a size of 50KDa
a n dw i d e l ye x p r e s s e di nm o s tb o d yt i s s u e s[ 2]. It is an
extracellular protein which shows the secondary and tertiary
structure of serpin and binds to collagen-1 and heparin. The
αβ-sheet is the dominant feature of the secondary structure
and comprises the core structural domain of the protein,
beingcloselyinvolvedindynamicmovementsthatarepartof
serpin function [3]. Existence of a reactive centre loop (RCL)
isanotherfeatureofserpins,anditisaproteinaserecognition
site and a critical component of the function of serpins [4].
PEDF contains an RCL structure but the function of this is
still unknown [4].
PEDF was originally isolated from the conditioned
medium of cultured human fetal retinal pigment epithelium
cells [4]. As mentioned before, it can be found in almost
all tissues but the highest amount of expression has been
observed in the eye, fetal and adult liver tissue, adult testis,
ovaries,placenta,andthepancreas.Asigniﬁcantreductionin
theexpressionofPEDFisfoundinsenescent(aging)cells[5].
PEDF is a pluripotent molecule with neurotrophic qual-
ities, and several biological activities have been ascribed
to it, including antiangiogenic, antiproliferative, prodiﬀer-
entiation, neuroprotective, anti-inﬂammatory, and antitu-
mour properties [6–8]. The antiangiogenic properties and
neurotrophic activities of the protein are due to peptides
derived from the N-terminal region of this protein, while
the C-terminal peptides interact with its membrane receptor
[7]. How PEDF controls all these biological processes
and how it intercepts growth-promoting signals, accelerates
cell death cascades, and prolongs cellular lifespan remains
widely unknown but it presumably binds to cell surface
receptors to trigger various signalling cascades. Evaluating
the expression of diﬀerent PEDF receptors (PEDF-Rs) could
help to determine the speciﬁc biological responses of PEDF.
Studies show that there are at least two diﬀerent PEDF-
Rs, speciﬁc to neural or endothelial cells, respectively
[9]. The signalling pathways activated by PEDF regulate
a number of key transcription factors including nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-
κB) [10], nuclear factor of activated T cells (NFATs) [11],
peroxisome proliferator-activated receptor (PPAR-γ)[ 12],
and the potent promigratory urokinase-type plasminogen
activator (uPA)/receptor (uPAR) system [8, 13].
1.2. Introduction to Stem Cell Biology. Stem cells are recog-
nisedbytwoimportantfeatures,ﬁrstlytheself-renewalprop-
erty and secondly the multilineage diﬀerentiation potential
[14]. These characteristics make stem cells a preferred2 Journal of Biomedicine and Biotechnology
candidateforcell-basedtherapyfordiseasessuchasneuronal
damage [15].
Generally, stem cells are divided into two groups based
on their origins: embryonic stem cells (ESCs) which are
harvestedfromtheinnercellmassofblastocystsandhavethe
ability to produce all three embryonic germ layers-ectoderm,
endoderm, and mesoderm and adult stem cells which are
criticalfortissuehomeostasis.Adultstemcellssupporttissue
regeneration and replacement of ongoing cell loss due to
natural cell death and injury. These cells can be found in
most tissues such as the brain, bone marrow, liver, and retina
[16, 17].
Stem cells divide via mitosis and produce one daughter
cell to replace the divided parent cell (and thereby maintain
the stem cell pool) and one other cell which will go through
the diﬀerentiation process. The cell which undergoes dif-
ferentiation can do so to diﬀerent types of cells. Recently,
a phenomenon known as trans-diﬀerentiation has been
identiﬁed which is when tissue-speciﬁc stem cells switch
their lineage to that of some other tissue under suitable
conditions. For example, bone marrow stem cells are able to
transdiﬀerentiate into skeletal muscle, smooth muscle, and
neuronal cells [18].
In spite of the unique properties of stem cells (self-
renewal and diﬀerentiation), adult stem cells stay dormant
throughmostoftheirlifetimeandareactivatedundercertain
circumstances by speciﬁc environmental factors [19]. The
speciﬁc surrounding environment includes stroma which
contains ﬁbroblasts, macrophages, neutrophils, endothelial
cells and other diﬀerentiated cells, and the microenviron-
ment around the stem cell [20].
The surrounding microenvironment of a stem cell is
known as the stem cell niche and it includes diﬀerent
signalling areas which helps the daughter cell commit to
diﬀerentfates.Stemcellsneedtobeheldwithinthenicheand
this happens via adhesion between stem cells and underlying
basement membrane or support cells. Upon division, if a
cell is placed outside the niche, it commits to diﬀerentiation
depending on the diﬀerent microenvironmental stimuli and
signalling it encounters in its new niche [19].
Stem cells have the capacity to react to a broad range
of growth factors and signalling molecules and express
many of the important downstream signal transduction
components such as those signal transduction pathways
that are present and may be active in stem cells. These
include Notch, transforming growth factor beta (TGFβ),
Wnt, bone morphogenetic proteins (BMPs), Hedgehog, and
Janus kinase/signal transducer and activator of transcription
(Jak/Stat) family members [21].
2.PEDFandStemCells
2.1. PEDF and Human Embryonic Stem Cells. Human
embryonic stem cells (hESCs) grown in vitro require feeder
cells such as ﬁbroblasts to maintain proliferation and
pluripotency. In a study using microarray analysis to study
the gene expression proﬁle of human foreskin ﬁbroblasts,
a number of molecular targets were identiﬁed that are
potentiallyinvolvedintheabilityofthesecellstoactasfeeder
cells for hESCs. The most likely target genes they found were
PEDF, c-Kit, and leptin. These ﬁndings were supported by
real-time polymerase chain reaction (RT-PCR) and virtual
serialanalysisofgeneexpression(SAGE)analysis.Ithasbeen
hypothesized that the protein products of these genes may
play an important role in the support of hESC growth by
human foreskin ﬁbroblasts [22].
Age-related macular degeneration (AMD) is one of
the common causes of blindness in the elderly and is
characterised by degeneration and loss of retinal pigmented
epithelial (RPE) cells and photoreceptor cells in the macular
region. Local expression of PEDF is signiﬁcantly decreased
in the eyes of patients with AMD [23]. There are two late
forms of the disease: in geographic atrophy (also known
as dry) there are conﬂuent areas of RPE degeneration and
loss in the macular region, while in neovascular AMD (also
known as wet), there is growth of blood vessels from the
choroidthroughBruch’smembranetothesubretinalspace—
a process known as choroidal neovascularization (CNV)
[24, 25].
hESC-derived retinal pigment epithelium (hES-RPE)
seems to be a promising strategy for cell replacement in
this condition. Studies have shown that polarised hES-
RPE cells secrete high levels of PEDF and that culture
medium containing this PEDF increased proliferation and
supported the survival of retinal progenitor cells (RPCs)
isolated from human fetal eyes [23]. This role of PEDF was
conﬁrmed by the addition of neutralising PEDF antibody to
theculturemedia,whichdiminishedorcompletelyabolished
the increase in RPC proliferation and survival.
Apart from the potential eﬀects of PEDF on RPCs, PEDF
also has at least three important eﬀects on the health of
RPEs. The ﬁrst eﬀect is the neuroprotective activity towards
photoreceptors and other retinal neural cells against damage
of cytotoxic injury. Second, its antiangiogenic eﬀect prevents
pathologicneovascularisationthroughinhibitingendothelial
cell migration and promoting endothelial apoptosis. Third,
its antiaging function inhibits premature senescence of both
RPE cells and their neighbouring retinal cells [26]( Table 1).
2.2. PEDF and Mesenchymal Stem Cells (MSCs). Bone
marrow-derived stem cells (BMSCs) are also called mes-
enchymal stem cells (MSCs) because these cells are able to
diﬀerentiate into a variety of mesodermal tissues includ-
ing bone, cartilage, and adipose [14]. One of the most
abundant proteins identiﬁed in murine mesenchymal MSC-
conditioned medium is PEDF [27]. Immunoﬂuorescent
staining shows a high level of expression of PEDF in the
rough endoplasmic reticulum/Golgi areas [27]. PEDF is also
found to be located near the plasma membrane and in the
extracellular space (considering the ability of PEDF to bind
to collagen and proteoglycans in the extracellular matrix).
Theroleofbone-marrow-derivedSCs(BMSCs)orMSCs
inangiogenesisisnotclearbutithasbeensuggestedthatthey
may support and stabilise newly formed blood vessels. The
process of angiogenesis is regulated by various factors that
stimulate or inhibit angiogenesis. One of the key factors thatJournal of Biomedicine and Biotechnology 3
Table 1: Eﬀects of PEDF on diﬀerent types of stem cells.
Stem cell type PEDF eﬀect Reference
Human embryonic stem cell Proliferation, support, and survival [22, 23]
Neural stem cell
Self-renewal
[31–33] Maintenance of multipotency
Activation of cell division
Antiapoptotic eﬀects
Retinal stem cell
Self-renewal
[35, 37, 38]
Cell expansion
Inhibits migration of and induces apoptosis of endothelial cells
Regression of CNV (at low doses)
Development of neovascularisation (at high doses)
Epiphyseal plate
Bone marrow cavity
(mesenchymal stem cell source)
Germinal zone (containing
stem cells) or resting zone (R)
Maturation zone (M)
Upper and lower hypertrophic zone
(UH, LH)
PEDF expression zone
Proliferative zone (P)
Ossiﬁcation zone (OZ)
Figure 1
stimulates angiogenesis is vascular endothelial growth factor
(VEGF). This factor is expressed in a wide range of cells
including BMSCs. On the other hand, one of the key func-
tions of the PEDF molecule is the inhibition of angiogenesis.
In a study by Fan et al. (2011), it was observed that PEDF
expression was much stronger than that of VEGF in BMSCs.
Based on data acquired during that project, the authors
concluded that BMSCs may not usually be an angiogenesis-
promoting population in a normal environment [28]. This
view was supported by other ﬁndings that, in the presence of
high cell numbers, MSCs are capable of inhibiting capillary
growth [29].
DuringdiﬀerentiationofMSCstoosteoblasts,expression
of several genes begins and this includes PEDF. It has
been shown that a high level of PEDF is expressed during
early stages of bone development by osteoblasts and to a
lesser extent in osteoclasts [30, 31]. Osteoblasts and possibly
osteoclasts are able to synthesise and release PEDF, and
this protein has a critical role in normal and abnormal
bone angiogenesis. In developing bones, blood vessel growth
is localised. In locations such as the long bone growth
plate, blood vessels selectively invade the region between
hypertrophic chondrocytes and newly formed bone matrix
(Figure 1). These newly formed vessels allow migration of
osteoblasts which leads to new bone matrix deposition
and bone elongation. PEDF is expressed in the epiphyseal
cartilage and in the areas of active bone remodelling in the
primary spongiosa and periosteum of metaphyseal bone.
There is a gradual decrease in the intensity of PEDF
expression as chondrocytes diﬀerentiate toward the base of
the growth plate [30, 32].
It has been found that PEDF secreted from enriched
mouse bone marrow cells exhibiting surface markers char-
acteristic of multipotent MSCs is able to attract ﬁbroblasts
and this property may play a role in regulating the cellular
proﬁle at the site of an injury. PEDF secretion happens in
early postinjury stages rather than late postinjury and is
due to the diﬀerent cellular requirements during diﬀerent
stages. For example, PEDF released by resident stem cells
may stimulate migration of cells needed early in regenera-
tion, such as ﬁbroblasts while inhibiting migration of cells
such as endothelial cells needed for capillary formation at
subsequent stages of healing [27].
2.3. PEDF and Neural Stem Cells (NSCs). In 2006 Ram´ ırez-
Castillejo et al. [33] showed that PEDF produced by the4 Journal of Biomedicine and Biotechnology
subventricular zone (SVZ) in the mouse brain promotes
self-renewal and invigoration of slowly dividing adult neural
stem cells (NSCs) in vitro [33]. It also stimulates the
expansion of the stem cell niche in brain and induces
diﬀerentiation toward the neuronal phenotype in multiple
cell types [34]. In the subependymal zone (SEZ) of the
adult mammalian brain, neuroblasts and oligodendrocytes
are produced from NSCs through fast-dividing transit-
amplifying progenitors (TAPs). Vascular elements and sev-
eral endothelium-derived factors are known to regulate
the proliferation and/or survival of neural progenitors and
PEDF is one of them. PEDF acts as an endogenous SEZ
niche factor that can evoke NSC expansionary divisions
[35].
Andreu-Agull´ o et al. (2009) found that PEDF could
modulate the balance between symmetric and asymmetric
divisions in NSCs. Essentially PEDF promoted self-renewing
divisions and maintenance of a multipotent state in NSCs
through its eﬀects on Notch transcriptional activity. The
mechanism by which this occurs appears to be complex.
Activation of Notch receptors by membrane bound ligands
results in the generation of an intracellular domain of Notch
(NICD) which moves to the nucleus, where it binds the
repressor C promoter-binding factor 1 (CBF1). CBF1 can
thenbindtothepromotersandinitiatetranscriptionofgenes
in the Hes1 and Herp families and, possibly, the Egfr gene
[35]. This results in the eﬀects of Notch signalling, that is,
increase in self-renewal of NSCs.
So what is the role of PEDF in all this? Notch activity
is attenuated by the interplay between transcriptional co-
activators and corepressors. One of these is N-CoR, which
is a corepressor for a number of nuclear receptors and can
bind to CBF1. It was postulated that the CBF1-binding sites
in the Hes1 and Egfr promoters were occupied by N-CoR,
repressing the transcription of these genes (Figure 2(a)). It
was found that, in the presence of PEDF, N-CoR moves from
a nuclear to cytoplasmic location and that PEDF removes
N-CoR (the repressor) from the CBF1-binding sites in the
promoters of the Hes1 and Efgr genes, thus allowing CBF1
(the inducer) to bind and activate these genes (Figure 2(b)).
Further experiments suggested that PEDF carries out these
activities through a noncanonical activation of the NF-κB
pathway [35].
2.4. Stem Cells Overexpressing the PEDF Gene. MSCs have
been shown to diﬀerentiate into endothelial cells (ECs)
and vascular smooth muscle cells (VSMCs) and incorporate
into the new blood vessel wall and form vascular tubes.
MSCs have an explicit role in various proangiogenic models
although, interestingly, they have an antiangiogenic eﬀect on
corneal wound healing after chemical injury [36]. Excessive
vascularisation can lead to pathological situations. Studies
show that MSCs contribute to the formation of choroidal
neovascularisation (CNV) and they can diﬀerentiate into
both vascular and extravascular cells in CNV [37]. CNV is a
major form of ocular angiogenesis which leads to visual loss.
The mechanism of CNV is complex but, basically, a dis-
rupted balance between angiogenic and antiangiogenic fac-
tors like VEGF as an angiogenic stimulator and PEDF as an
CBF1
P
Nucleus
P
CBF1
Egfr Hes1
N-CoR N-CoR
(a)
Cytoplasm
PEDF PEDF
Nucleus
P
CBF1
P
CBF1
Egfr Hes1
N-CoR
N-CoR
(b)
Figure 2
inhibitor of angiogenesis is the cause. It has been suggested
that PEDF may cause regression of CNV promoted by VEGF
[38]. The eﬀects of PEDF on CNV are complicated: while
PEDF suppresses the growth of endothelial cells exposed
to ﬁbroblast growth factor-2 (FGF2), it evokes proliferation
of endothelial cells in the presence of high VEGF levels.
In another report, PEDF showed concentration-dependent
eﬀects on CNV and endothelial cell function: low doses are
inhibitory, but high doses can increase neovascularisation
[39].
In a study by Hou et al. (2010), it was observed
that injecting MSCs transduced with adenoviral vectors
expressing PEDF (AdPEDF) caused a regression in neovas-
cularisation as a result of the CNVs being encapsulated in
retinal pigment epithelial cells (RPEs) [37].
Deterioration of photoreceptor cells may be caused by
a continuous degeneration of retinal pigment epithelium
(RPE) cells and can lead to vision loss. Adenovirally trans-
duced bone marrow stromal (stem) cells carrying the PEDF
gene exhibited the typical morphologies of RPE cells in
vitro. Furthermore, when these cells were injected into the
superior subretinal space of Royal College of Surgeons (RCS)
rats, a well-established model of retinal degeneration due
to defective phagocytosis of photoreceptor outer segments
by the RPE, these cells produced more pronounced rescue
eﬀects than nontransduced cells. This suggests that PEDF
haspotencytoprotectphotoreceptorcellsfromdegeneration
[40].
Stem cell therapy, especially using MSCs, has been
considered as a promising method for treating myocardial
infarction (MI) [41]. In a study where myocardial infarction
was induced in C57BL/6 mice, it had been observed that
MSCs could ameliorate MI injury, but that MSCs derived
from older donors had less eﬃcacy. It was found that olderJournal of Biomedicine and Biotechnology 5
MSCssecretedhigherlevelsofPEDFthanyoungerones.Fur-
thermore,infarctstreatedwith(AdPEDF-)transducedMSCs
that over-expressed PEDF contained fewer ECs, VSMCs, and
macrophages but had increased number of ﬁbroblasts [42].
They concluded that it was the increased expression of PEDF
in aged MSCs that impaired their therapeutic eﬃcacy.
3. Conclusion
PEDF has a range of functions in diﬀerent tissues and cells;
however, the impact of this interesting protein on stem
cells is not yet clear. PEDF expressed in feeder cells appears
to have a supportive eﬀect on stem cells such as hESCs
and RPCs. PEDF aﬀects NSCs via the Notch transcriptional
pathway, promoting self-renewing divisions, maintaining a
multipotent state of these cells and supporting expansion of
the stem cell niche. Stem cells transduced with adenoviral
vectors carrying PEDF exhibit potential for enhanced stem
cell therapy in diseases such as macular degeneration.
However, the eﬀects of PEDF on stem cells in other disease
states are clear. Whilst PEDF generally causes regression of
CNV established by VEGF, the eﬀects may be concentration
dependent—both on the concentration of VEGF and PEDF.
As for myocardial infarction, the presence of excessive PEDF
is actually reported to reduce the eﬃcacyofstemcelltherapy.
To conclude, the role of PEDF in stem cells in various
pathologiesdoesdiﬀer,andwhilecounterproductiveinsome
cases such as myocardial infarction, it may have a positive
role to play in some instances. Further studies on PEDF and
stem cells will help illuminate such instances and whether
they can be used therapeutically.
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